Johnson & Johnson scored a critical victory on Wednesday after a jury rendered a defense verdict in the first bellwether trial over the blood thinner Xarelto.
The drug has become a poster child for tort reformers who object to rampant advertising by plaintiffs attorneys in cases involving pharmaceuticals and medical devices. Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. and Bayer brought in powerhouse litigator Beth Wilkinson of Washington, D.C.’s Wilkinson Walsh + Eskovitz to lead the defense team at trial, which took place in New Orleans.
